Trials / Enrolling By Invitation
Enrolling By InvitationNCT06851403
The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 213 (estimated)
- Sponsor
- Guangzhou Institute of Respiratory Disease · Academic / Other
- Sex
- All
- Age
- 4 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks |
Timeline
- Start date
- 2022-01-30
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2025-02-28
- Last updated
- 2025-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06851403. Inclusion in this directory is not an endorsement.